Alkermes - ALKS Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALKS shares.
View ALKS analyst ratings or view top-rated stocks.

8 Wall Street research analysts have issued twelve-month price objectives for Alkermes' stock. Their ALKS share price forecasts range from $25.00 to $36.00. On average, they expect the company's stock price to reach $30.10 in the next twelve months. This suggests a possible upside of 5.6% from the stock's current price.
View analysts price targets for ALKS or view top-rated stocks among Wall Street analysts.

Alkermes' stock was trading at $26.13 at the beginning of 2023. Since then, ALKS stock has increased by 9.1% and is now trading at $28.50.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 15th 2023.
View our ALKS earnings forecast.

Alkermes plc (NASDAQ:ALKS) issued its quarterly earnings data on Wednesday, November, 2nd. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01. The firm had revenue of $252.36 million for the quarter, compared to analyst estimates of $271.45 million. Alkermes had a negative trailing twelve-month return on equity of 1.10% and a negative net margin of 11.41%. The company's quarterly revenue was down 14.2% compared to the same quarter last year. During the same period last year, the company posted ($0.02) earnings per share.

Alkermes issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share guidance of $0.15-$0.33 for the period, compared to the consensus earnings per share estimate of $0.20. The company issued revenue guidance of $1.07 billion-$1.12 billion, compared to the consensus revenue estimate of $1.10 billion.

119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Alkermes' stock is owned by many different retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.10%), Paradiem LLC (0.03%), Harbor Capital Advisors Inc. (0.02%), Strs Ohio (0.02%), Diversified Trust Co (0.02%) and Dupont Capital Management Corp (0.01%). Insiders that own company stock include Blair Curtis Jackson, Christian Todd Nichols, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Richard F Pops, Shane Cooke and Wendy L Dixon.
View institutional ownership trends.

Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALKS stock can currently be purchased for approximately $28.50.

Alkermes (NASDAQ:ALKS) has a market capitalization of $4.68 billion and generates $1.17 billion in revenue each year. The company earns $-48,170,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.

The company employs 2,211 workers across the globe.

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The official website for the company is www.alkermes.com. The company can be reached via phone at (531) 772-8000, via email at investor_relations@alkermes.com, or via fax at 781-890-0524.